{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:04:41Z","timestamp":1758672281841,"version":"3.44.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["19363"],"award-info":[{"award-number":["19363"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-136898","MOP-142316"],"award-info":[{"award-number":["MOP-136898","MOP-142316"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2014-04810","RGPIN-2019-04786"],"award-info":[{"award-number":["RGPIN-2014-04810","RGPIN-2019-04786"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.virol.2021.06.005","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T07:59:38Z","timestamp":1624003178000},"page":"87-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector"],"prefix":"10.1016","volume":"561","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-8903","authenticated-orcid":false,"given":"Ryan G.","family":"Clarkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Del Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy L.","family":"Poulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin J.","family":"Parks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2021.06.005_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/292420a0","article-title":"Controls of RNA splicing and termination in the major late adenovirus transcription unit","volume":"292","author":"Akusj\u00e4rvi","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.virol.2021.06.005_bib2","series-title":"Molecular Design of Oncolytic Adenoviruses, Adenoviral Vectors for Gene Therapy","first-page":"319","author":"Alemany","year":"2016"},{"key":"10.1016\/j.virol.2021.06.005_bib3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/77283","article-title":"Replicative adenoviruses for cancer therapy","volume":"18","author":"Alemany","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.virol.2021.06.005_bib4","doi-asserted-by":"crossref","DOI":"10.3791\/52065-v","article-title":"Viral concentration determination through plaque assays: using traditional and novel overlay systems","author":"Baer","year":"2014","journal-title":"JoVE"},{"key":"10.1016\/j.virol.2021.06.005_bib5","first-page":"6566","article-title":"Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells","volume":"62","author":"Bateman","year":"2002","journal-title":"Canc. Res."},{"key":"10.1016\/j.virol.2021.06.005_bib6","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1073\/pnas.91.19.8802","article-title":"An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3","volume":"91","author":"Bett","year":"1994","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.virol.2021.06.005_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.virol.2021.06.005_bib8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/jgm.754","article-title":"Replication\u2010dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice\u2010acceptor site","volume":"7","author":"Carette","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.virol.2021.06.005_bib9","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/sj.gt.3303008","article-title":"GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model","volume":"14","author":"Cascante","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/cgt.2011.84","article-title":"A novel conditionally replicating adenoviral vector with dual expression of IL-24 and arresten inserted in E1 and the region between E4 and fiber for improved melanoma therapy","volume":"19","author":"Chai","year":"2012","journal-title":"Canc. Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib11","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/jvi.70.7.4805-4810.1996","article-title":"Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli","volume":"70","author":"Chartier","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0092-8674(78)90019-3","article-title":"The spliced structures of adenovirus 2 fiber message and the other late mRNAs","volume":"15","author":"Chow","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.06.005_bib13","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1128\/JVI.00314-14","article-title":"Lysophosphatidylcholine reversibly arrests pore expansion during syncytium formation mediated by diverse viral fusogens","volume":"88","author":"Ciechonska","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tim.2014.08.005","article-title":"Reovirus FAST proteins: virus-encoded cellular fusogens","volume":"22","author":"Ciechonska","year":"2014","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2021.06.005_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1099\/vir.0.026013-0","article-title":"Homomultimerization of the reovirus p14 fusion-associated small transmembrane protein during transit through the ER\u2013Golgi complex secretory pathway","volume":"92","author":"Corcoran","year":"2011","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib16","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1128\/JVI.78.8.4342-4351.2004","article-title":"Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell-cell fusion","volume":"78","author":"Corcoran","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.cgt.7701117","article-title":"Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad [I\/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region","volume":"15","author":"Danielsson","year":"2008","journal-title":"Canc. Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib18","article-title":"Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic","author":"Del Papa","year":"2020","journal-title":"Canc. Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/v9010013","article-title":"Adenoviral vectors armed with cell fusion-inducing proteins as anti-cancer agents","volume":"9","author":"Del Papa","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2021.06.005_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omto.2019.05.001","article-title":"An oncolytic adenovirus vector expressing p14 FAST protein induces widespread syncytium formation and reduces tumor growth rate in vivo","volume":"14","author":"Del Papa","year":"2019","journal-title":"Molecular Therapy-Oncolytics"},{"key":"10.1016\/j.virol.2021.06.005_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s42003-020-0849-9","article-title":"Deep splicing plasticity of the human adenovirus type 5 transcriptome drives virus evolution","volume":"3","author":"Donovan-Banfield","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.virol.2021.06.005_bib22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/viro.2002.1772","article-title":"Overexpression of the ADP (E3-11.6 K) protein increases cell lysis and spread of adenovirus","volume":"305","author":"Doronin","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.virol.2021.06.005_bib23","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/JVI.74.13.6147-6155.2000","article-title":"Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein","volume":"74","author":"Doronin","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib24","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/0008-5472.CAN-03-3753","article-title":"Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer","volume":"64","author":"Ebert","year":"2004","journal-title":"Canc. Res."},{"key":"10.1016\/j.virol.2021.06.005_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.gt.3302609","article-title":"Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming","volume":"13","author":"Errington","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145158","article-title":"Arming oncolytic adenoviruses: effect of insertion site and splice acceptor on transgene expression and viral fitness","volume":"21","author":"Farrera-Sal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virol.2021.06.005_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041034","article-title":"Effect of transgene location, transcriptional control elements and transgene features in armed oncolytic adenoviruses","volume":"12","author":"Farrera-Sal","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.virol.2021.06.005_bib28","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/ijc.29258","article-title":"Genetic delivery of an immuno RN ase by an oncolytic adenovirus enhances anticancer activity","volume":"136","author":"Fern\u00e1ndez\u2010Ulibarri","year":"2015","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.virol.2021.06.005_bib29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1525-0016(03)00092-3","article-title":"Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect","volume":"7","author":"Fu","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.virol.2021.06.005_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1099\/vir.0.83444-0","article-title":"Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping","volume":"89","author":"Funston","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib32","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.01054-08","article-title":"A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P\/V mutant without compromising sensitivity to type I interferon","volume":"82","author":"Gainey","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib33","first-page":"798","article-title":"A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer","volume":"6","author":"Ganly","year":"2000","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.virol.2021.06.005_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.cgt.7700801","article-title":"Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors","volume":"12","author":"Garc\u00eda-Castro","year":"2005","journal-title":"Canc. Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib35","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","article-title":"In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors","volume":"51","author":"Giard","year":"1973","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.virol.2021.06.005_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"10.1016\/j.virol.2021.06.005_bib37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1099\/0022-1317-68-3-937","article-title":"Growth of 293 cells in suspension culture","volume":"68","author":"Graham","year":"1987","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib39","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/gt.2008.94","article-title":"Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication","volume":"15","author":"Guedan","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib40","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.virol.2021.06.005_bib41","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2021.06.005_bib42","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1128\/JVI.00033-16","article-title":"Morphological, biochemical, and functional study of viral replication compartments isolated from adenovirus-infected cells","volume":"90","author":"Hidalgo","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib43","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1158\/1535-7163.MCT-06-0790","article-title":"Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer","volume":"6","author":"Hoffmann","year":"2007","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.virol.2021.06.005_bib44","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2020.11.FOCUS20839","article-title":"Inhibition of glioma using a novel non-neurotoxic vesicular stomatitis virus","volume":"50","author":"Jiang","year":"2021","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.virol.2021.06.005_bib45","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ymthe.2005.07.696","article-title":"Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression","volume":"12","author":"Jin","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib46","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virol.2021.06.005_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/cancers10070216","article-title":"Fusogenic viruses in oncolytic immunotherapy","volume":"10","author":"Krabbe","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.virol.2021.06.005_bib48","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","article-title":"Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results","volume":"21","author":"Lang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.virol.2021.06.005_bib49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0022-2836(92)90922-7","article-title":"Control of adenovirus major late gene expression at multiple levels","volume":"225","author":"Larsson","year":"1992","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2021.06.005_bib50","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/mt.2010.44","article-title":"Synergistic interaction between oncolytic viruses augments tumor killing","volume":"18","author":"Le Boeuf","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omto.2017.08.001","article-title":"Reovirus FAST protein enhances vesicular stomatitis virus oncolytic virotherapy in primary and metastatic tumor models","volume":"6","author":"Le Boeuf","year":"2017","journal-title":"Molecular Therapy - Oncolytics"},{"key":"10.1016\/j.virol.2021.06.005_bib52","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1089\/10430340152710504","article-title":"Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles","volume":"12","author":"Li","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/08830180490265556","article-title":"Functions and mechanisms of action of the adenovirus E3 proteins","volume":"23","author":"Lichtenstein","year":"2004","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.virol.2021.06.005_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0378-1119(82)90186-X","article-title":"Tn5 mutagenesis of the transforming genes of human adenovirus type 5","volume":"19","author":"McKinnon","year":"1982","journal-title":"Gene"},{"key":"10.1016\/j.virol.2021.06.005_bib55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ymthe.2004.01.012","article-title":"Use of adenovirus protein IX (pIX) to display large polypeptides on the virion--generation of fluorescent virus through the incorporation of pIX-GFP","volume":"9","author":"Meulenbroek","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib56","doi-asserted-by":"crossref","first-page":"10074","DOI":"10.1128\/JVI.02665-09","article-title":"Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX","volume":"84","author":"Poulin","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01112-20","article-title":"Fusion of large polypeptides to human adenovirus type 5 capsid protein IX can compromise virion stability and DNA packaging capacity","volume":"94","author":"Poulin","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.virol.2011.09.004","article-title":"Use of Cre\/loxP recombination to swap cell binding motifs on the adenoviral capsid protein IX","volume":"420","author":"Poulin","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.virol.2021.06.005_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.virol.2003.11.028","article-title":"Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo","volume":"320","author":"Rivera","year":"2004","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.virol.2021.06.005_bib60","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot5011","article-title":"Construction and characterization of adenovirus vectors","volume":"4","author":"Ross","year":"2009","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.virol.2021.06.005_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00088-19","article-title":"Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses human adenovirus gene expression and replication","volume":"93","author":"Saha","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib62","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.virol.2020.07.007","article-title":"Identification of human adenovirus replication inhibitors from a library of small molecules targeting cellular epigenetic regulators","volume":"555","author":"Saha","year":"2021","journal-title":"Virology"},{"key":"10.1016\/j.virol.2021.06.005_bib63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.virol.2019.09.005","article-title":"Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus","volume":"538","author":"Saha","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.virol.2021.06.005_bib64","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1128\/JVI.79.13.8090-8100.2005","article-title":"Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability","volume":"79","author":"Salsman","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/104303403321467199","article-title":"Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points","volume":"14","author":"Sauthoff","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib66","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-05-4352","article-title":"Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control","volume":"66","author":"Simpson","year":"2006","journal-title":"Canc. Res."},{"key":"10.1016\/j.virol.2021.06.005_bib67","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1089\/hum.2010.227","article-title":"Strategies to enhance viral penetration of solid tumors","volume":"22","author":"Smith","year":"2011","journal-title":"Hum. Gene Ther."},{"year":"2014","series-title":"World Cancer Report 2014","author":"Stewart","key":"10.1016\/j.virol.2021.06.005_bib68"},{"key":"10.1016\/j.virol.2021.06.005_bib69","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.virol.2021.06.005_bib70","first-page":"3348","article-title":"The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses","volume":"8","author":"Suzuki","year":"2002","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.virol.2021.06.005_bib71","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1743-422X-8-294","article-title":"A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma","volume":"8","author":"Takaoka","year":"2011","journal-title":"Virol. J."},{"key":"10.1016\/j.virol.2021.06.005_bib72","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0092-8674(80)90362-1","article-title":"DNA replication and the early to late transition in adenovirus infection","volume":"22","author":"Thomas","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.virol.2021.06.005_bib73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/viro.1996.0295","article-title":"The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with ADP mutants","volume":"220","author":"Tollefson","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.virol.2021.06.005_bib74","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/jvi.70.4.2296-2306.1996","article-title":"The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells","volume":"70","author":"Tollefson","year":"1996","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.virol.2021.06.005_bib75","first-page":"e01869","article-title":"The human adenovirus type 2 transcriptome: an amazing complexity of alternatively spliced mRNAs","volume":"95","author":"Westergren Jakobsson","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/cgt.2016.41","article-title":"Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer","volume":"23","author":"Wong","year":"2016","journal-title":"Canc. Gene Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib77","article-title":"Adenovirus-mediated expression of the p14 fusion-associated small transmembrane protein promotes cancer cell fusion and apoptosis in vitro but does not provide therapeutic efficacy in a xenograft mouse model of cancer","volume":"11","author":"Wong","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.virol.2021.06.005_bib78","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2009.266","article-title":"Current issues and future directions of oncolytic adenoviruses","volume":"18","author":"Yamamoto","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2021.06.005_bib79","first-page":"4200","article-title":"The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts","volume":"59","author":"Yu","year":"1999","journal-title":"Canc. Res."},{"key":"10.1016\/j.virol.2021.06.005_bib80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2014.04.006","article-title":"A new look at adenovirus splicing","volume":"456\u2013457","author":"Zhao","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.virol.2021.06.005_bib81","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1128\/JVI.79.9.5455-5465.2005","article-title":"Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses","volume":"79","author":"Zhu","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2021.06.005_bib82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.virol.2004.06.007","article-title":"Overexpression of adenovirus E3-11.6 K protein induces cell killing by both caspase-dependent and caspase-independent mechanisms","volume":"326","author":"Zou","year":"2004","journal-title":"Virology"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682221001355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682221001355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:55:30Z","timestamp":1758588930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682221001355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":82,"alternative-id":["S0042682221001355"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2021.06.005","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2021.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}